Literature DB >> 28587385

GnRH antagonist for patients with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer in fresh cycles.

Xiang-Hong Zhai1,2, Ping Zhang2,3, Feng-Xia Wu4, An-Cong Wang2,3, Pei-Shu Liu5.   

Abstract

The aim of the present study was to evaluate the influence of a gonadotropin-releasing hormone (GnRH) antagonist compared with a GnRH agonist on the in vitro fertilization cycle outcome in patients with polycystic ovary syndrome. The outcomes of pregnancy were evaluated. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was also used to evaluate whether the endometrial thickness (cm) and estradiol (E2) level (pg/ml) on the day of human chorionic gonadotropin (hCG) administration (the hCG day) had the best sensitivity and specificity for predicting a clinical pregnancy. The results demonstrated that there were significant differences in the E2 and progesterone levels between the two treatment groups on the hCG day. Furthermore, the mean number of total oocytes retrieved, mean number of 2 pronuclei oocytes, mean number of oocytes cleaved (P<0.05), mean number of embryos available (P=0.022) and mean number of embryos transferred (P=0.014) were significantly different. Additionally, the rates of ectopic pregnancy (P=0.984) and ovarian hyperstimulation syndrome (P=0.976) did not differ significantly between the treatment groups. Although the biochemical pregnancy (P=0.592), clinical pregnancy (P=0.617) and live birth (P=0.365) rates were lower with the GnRH antagonist than with the GnRH agonist, there were no significant differences in the outcomes between the two groups. Analysis of the influence of endometrial thickness with respect to the clinical pregnancy using the ROC (AUC) method revealed that when the best cutoff of 9.75 cm was used, the sensitivity was 62.5%, the specificity was 43.1% and the AUC was 0.53. Additionally, the Youden index was 0.056. Analysis of the influence of the E2 level on the hCG day on clinical pregnancy, using the ROC (AUC) method showed that the best cutoff was 2,984.5 pg/ml, which had a sensitivity of 68.8% and specificity of 52.9%, while the AUC was 0.573 (with a Youden index of 0.217). Furthermore, the results demonstrated that neither the endometrial thickness nor the E2 level on the hCG day had the best sensitivity and specificity for predicting a clinical pregnancy.

Entities:  

Keywords:  clinical pregnancy; fresh cycle; gonadotrophin-releasing hormone antagonist; in vitro fertilization and embryo transfer; ovarian hyperstimulation syndrome; polycystic ovary syndrome

Year:  2017        PMID: 28587385      PMCID: PMC5450517          DOI: 10.3892/etm.2017.4309

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  22 in total

Review 1.  Gonadotropin-releasing-hormone-receptor antagonists.

Authors:  J A Huirne; C B Lambalk
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

Review 2.  Can we eliminate severe ovarian hyperstimulation syndrome?

Authors:  Raoul Orvieto
Journal:  Hum Reprod       Date:  2004-11-26       Impact factor: 6.918

3.  GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis.

Authors:  G Griesinger; K Diedrich; B C Tarlatzis; E M Kolibianakis
Journal:  Reprod Biomed Online       Date:  2006-11       Impact factor: 3.828

Review 4.  Inflammation and implantation.

Authors:  Nava Dekel; Yulia Gnainsky; Irit Granot; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2010-01       Impact factor: 3.886

Review 5.  World Health Organization reference values for human semen characteristics.

Authors:  Trevor G Cooper; Elizabeth Noonan; Sigrid von Eckardstein; Jacques Auger; H W Gordon Baker; Hermann M Behre; Trine B Haugen; Thinus Kruger; Christina Wang; Michael T Mbizvo; Kirsten M Vogelsong
Journal:  Hum Reprod Update       Date:  2009-11-24       Impact factor: 15.610

6.  Mitochondrial distribution and activity in human mature oocytes: gonadotropin-releasing hormone agonist versus antagonist for pituitary down-regulation.

Authors:  Maria Elena Dell'Aquila; Barbara Ambruosi; Teresa De Santis; Yoon Sung Cho
Journal:  Fertil Steril       Date:  2008-03-25       Impact factor: 7.329

7.  What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization?

Authors:  Raoul Orvieto; Simion Meltcer; Roy Homburg; Ravit Nahum; Jacob Rabinson; Jacob Ashkenazi
Journal:  Fertil Steril       Date:  2008-09-06       Impact factor: 7.329

Review 8.  Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review.

Authors:  H G Al-Inany; A M Abou-Setta; M Aboulghar
Journal:  Reprod Biomed Online       Date:  2007-05       Impact factor: 3.828

9.  Endometrial thickness affects the outcome of in vitro fertilization and embryo transfer in normal responders after GnRH antagonist administration.

Authors:  Yu Wu; Xiaohong Gao; Xiang Lu; Ji Xi; Shan Jiang; Yin Sun; Xiaowei Xi
Journal:  Reprod Biol Endocrinol       Date:  2014-10-09       Impact factor: 5.211

10.  Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis.

Authors:  Jin-song Xiao; Cun-mei Su; Xian-tao Zeng
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more
  2 in total

1.  Influence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles.

Authors:  Yang Xu; Yu-Song Zhang; Dong-Yi Zhu; Xiang-Hong Zhai; Feng-Xia Wu; An-Cong Wang
Journal:  Biomed Rep       Date:  2018-11-29

2.  Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?

Authors:  Neeta Singh; Neha Mishra; Yogita Dogra
Journal:  J Hum Reprod Sci       Date:  2021-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.